FDA label
What is Ninlaro used for?
Ninlaro contains ixazomib. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “NINLARO® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Ninlaro?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Ninlaro, capsule
Indications and Usage, quoted from the label by Takeda Pharmaceuticals America, Inc. (NDA208462). Cross-references to other label sections are left out.
NINLARO® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Limitations of Use: NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.
Source: DailyMed label, set id 038f2461-834b-4488-9ebd-863c83eef5a7, version 18, effective August 11, 2026. NDC 63020-230, one of 3 listings for this product.
Questions
What is Ninlaro used for?
The FDA label says: “NINLARO® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.”
What drug class is Ninlaro?
FDA lists ixazomib in the Proteasome Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.